Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications

Opinion
Video

Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.

Recent Videos
4 experts in this video
4 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Related Content